{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-003372","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.316477+00:00","generated_at":"2026-05-24T04:18:48.593320+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance","bullets":["STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).","Inflammatory lesion count reduced by 16.8 vs 13.1 (p<0.001); non-inflammatory by 17.3 vs 12.4 (p<0.001).","XYNGARI safe and well tolerated; no serious treatment-related adverse events.","Plans to initiate second Phase 3 STAR-2 trial in H2 2025, followed by NDA submission if positive.","CEO cites potential for partnership discussions; over 30 million U.S. acne patients annually."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-003372","json":"https://secwatch.observer/filing/0001654954-25-003372.json","markdown":"https://secwatch.observer/filing/0001654954-25-003372.md","text":"https://secwatch.observer/filing/0001654954-25-003372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/0001654954-25-003372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:18:48.593320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}